image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

Babcock

September 2023

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • BAB
  • Price:
  • 393p
The shares soared £1 after Babcock unveiled revenue, profit and cash metrics comfortably ahead of  estimates and consensus for the year. Cash performance in H2 was particularly strong, reducing net debt to £564.4m (versus Berenberg at £597m) with net debt / EBITDA falling from 1.8x to 1.5x in FY23. Revenue rose 10% adjusting for disposals while underlying operating profit excluding the £100m Type 31 charge (the dispute resolution process is ongoing) was £278m, 8% above consensus. Eps were 33.8p. The contract backlog increased 7% organically to £9.5bn (excluding £3.4bn of framework contracts), visibility is good, with c£2.8bn of revenue under contract at the start of FY24, and c£700m of framework orders are expected to be delivered ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author